Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia.
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Gut. 2021 Sep;70(9):1691-1697. doi: 10.1136/gutjnl-2020-321753. Epub 2020 Nov 10.
Large (≥20 mm) sessile serrated lesions (L-SSL) are premalignant lesions that require endoscopic removal. Endoscopic mucosal resection (EMR) is the existing standard of care but carries some risk of adverse events including clinically significant post-EMR bleeding and deep mural injury (DMI). The respective risk-effectiveness ratio of piecemeal cold snare polypectomy (p-CSP) in L-SSL management is not fully known.
Consecutive patients referred for L-SSL management were treated by p-CSP from April 2016 to January 2020 or by conventional EMR in the preceding period between July 2008 and March 2016 at four Australian tertiary centres. Surveillance colonoscopies were conducted at 6 months (SC1) and 18 months (SC2). Outcomes on technical success, adverse events and recurrence were documented prospectively and then compared retrospectively between the subsequent time periods.
A total of 562 L-SSL in 474 patients were evaluated of which 156 L-SSL in 121 patients were treated by p-CSP and 406 L-SSL in 353 patients by EMR. Technical success was equal in both periods (100.0% (n=156) vs 99.0% (n=402)). No adverse events occurred in p-CSP, whereas delayed bleeding and DMI were encountered in 5.1% (n=18) and 3.4% (n=12) of L-SSL treated by EMR, respectively. Recurrence rates following p-CSP were similar to EMR at 4.3% (n=4) versus 4.6% (n=14) and 2.0% (n=1) versus 1.2% (n=3) for surveillance colonoscopy (SC)1 and SC2, respectively.
In a historical comparison on the endoscopic management of L-SSL, p-CSP is technically equally efficacious to EMR but virtually eliminates the risk of delayed bleeding and perforation. p-CSP should therefore be considered as the new standard of care for L-SSL treatment.
大(≥20mm)无蒂锯齿状病变(L-SSL)是一种癌前病变,需要进行内镜下切除。内镜黏膜切除术(EMR)是目前的标准治疗方法,但存在一些不良事件的风险,包括临床意义上的 EMR 后出血和深层壁损伤(DMI)。在 L-SSL 管理中,分片冷圈套息肉切除术(p-CSP)的风险-效果比尚不完全清楚。
2016 年 4 月至 2020 年 1 月,连续就诊的 L-SSL 患者在澳大利亚的四个三级中心接受 p-CSP 治疗,2008 年 7 月至 2016 年 3 月期间采用传统 EMR 治疗。在 6 个月(SC1)和 18 个月(SC2)进行监测结肠镜检查。前瞻性记录技术成功率、不良事件和复发情况,并在后续时间点进行回顾性比较。
共评估了 474 例患者的 562 个 L-SSL,其中 121 例患者的 156 个 L-SSL 接受 p-CSP 治疗,353 例患者的 406 个 L-SSL 接受 EMR 治疗。两个时期的技术成功率均相等(100.0%(n=156)与 99.0%(n=402))。p-CSP 组未发生不良事件,而 EMR 组分别有 5.1%(n=18)和 3.4%(n=12)的患者发生延迟出血和 DMI。p-CSP 组的复发率与 EMR 组相似,分别为 SC1 时的 4.3%(n=4)与 4.6%(n=14)和 SC2 时的 2.0%(n=1)与 1.2%(n=3)。
在 L-SSL 内镜治疗的历史比较中,p-CSP 在技术上与 EMR 同样有效,但可完全消除延迟出血和穿孔的风险。因此,p-CSP 应被视为 L-SSL 治疗的新标准。